Hamamatsu Photonics UK and the Medical Technologies Innovation Facility (MTIF) have entered into a partnership agreement in a bid to accelerate the development and availability of new medical and pharmaceutical therapies.
This new collaboration aims to leverage the photonics expertise, novel proprietary technology and applications of Hamamatsu, with the medical technology research and development capabilities of MTIF.
Tim Stokes, managing director of Hamamatsu Photonics UK, said: “Hamamatsu has a long history in developing cutting edge scientific equipment for the life science market; our FDSS/µCELL enables scientists, such as those working at MTIF, to make breakthroughs in the field of drug discovery and compound research.
“We are really excited about this new partnership between Hamamatsu and the team at MTIF helping to make such advanced instrumentation available to hundreds of potential users throughout the UK research community.”
The FDSS/μCELL is a compact screening system that enables monitoring of GPCRs and ion channels for drug discovery and life science research. Screening various compounds at high throughput is enabled by fluorescence or luminescence measurements using a highly sensitive Hamamatsu camera, which captures cell dynamics under the same conditions with no time lag between wells.
Through this collaboration, the two organisations will integrate their respective advanced technologies and development capabilities to showcase this laboratory screening technology on-site at MTIF in Nottingham.
Mike Hannay, managing director of MTIF, said: “This partnership provides companies with a unique opportunity to use cutting edge high through-put technology to screen compounds for pharmacological activity.
“These capabilities are usually unavailable to all but the largest organisations. This collaboration allows organisations of every size the opportunity to accelerate their drug discovery programme.”